Printer Friendly

OmniSonics Medical Technologies Announces Initial Results of Coronary Studies at Cardiac Symposium.

Business Editors/Health/Medical Writers

Society for Cardiac Angiography and Interventions, 26th Annual

Scientific Sessions


Initial Results Demonstrate Effectiveness of Novel Acoustic Energy Device in Resolving Occlusions in Coronary Arteries

OmniSonics Medical Technologies, developer of products based on the OmniWave(TM) Technology platform to treat vascular occlusive disease, announced initial results of preclinical studies of the Resolution(R) System to treat occlusions in coronary arteries. This data will be showcased at the Society for Cardiac Angiography and Interventions (SCAI) 26th Annual Scientific Sessions being held May 7th through 10th in Boston.

Dr. Sung Choi, of Tufts-New England Medical Center, tested the feasibility and safety of OmniSonics' ultrasonic technology to resolve blockages in the coronary arteries of swine. These blockages can take many forms including blood clots, plaque or calcific materials that obstruct flow in the arteries and in bypass grafts. The results from initial studies in animals indicate that the technology may be effective for thrombus (blood clot) resolution during coronary interventions.

OmniSonics is developing a novel acoustic technology to treat life-threatening occlusions that block blood vessels throughout the body. Based on the OmniWave Technology platform, the Resolution System is designed to resolve occlusions which occur as a result of coronary artery disease, hemodialysis access grafts, deep vein thrombosis and peripheral artery disease. The device, consisting of a thin, titanium wire that is placed into a clogged artery or vein, delivers low power, acoustic energy in all directions to resolve blood clots into minute particles approximately the size of red blood cells.

"Coronary artery disease is the leading cause of death in the developed world. It is imperative that cardiologists remove blockages in arteries in a manner that does not damage vessel walls, stents or synthetic bypass grafts," said Robert Rabiner, President and Chief Executive Officer of OmniSonics. "We are pleased to announce initial results of preclinical studies which demonstrate our successful use of OmniWave Technology in the coronary vasculature."

The poster presentation entitled, "Preclinical Feasibility and Acute Safety of a Transverse Cavitation Ultrasonic Guidewire for Intracoronary Ablation of Thrombus" will be available to the audience of interventional cardiologists, and other cardiovascular physicians.

The Resolution System has been designed to work alone or in conjunction with existing interventional approaches including balloon angioplasty, stent placement and pharmaceutical treatments. Over 60 patents and patent applications worldwide protect the OmniWave Technology. The Resolution System has received CE Mark approval and is the subject of ongoing clinical trials in the United States.

About OmniSonics Medical Technologies, Inc.

OmniSonics Medical Technologies, Inc., based in Wilmington, MA, is a privately held medical device company focused on bringing breakthrough products for vascular occlusive disease to market. These products are based on the Company's patented OmniWave(TM) Technology, the first technology that enables the delivery of acoustic energy over the active length of a small diameter wire in an occluded blood vessel. OmniWave Technology is designed to have broad applications in peripheral and coronary vascular occlusive conditions, which afflict millions of people worldwide. Robert Rabiner, Co-Founder and CEO of OmniSonics was recently honored by the World Economic Forum as a "Technology Pioneer for 2003" for the innovation of this "radical and transformational" technology. Rabiner was also named as one of Fast Company's "Fast 50" Champions of Innovation in 2002. The Resolution System bears the CE Mark and is available for sale in Europe. The Resolution System is the subject of an ongoing clinical investigation in the United States and is not commercially available in the U.S. For more information on OmniSonics Medical Technologies, visit the Company Website at

Certain statements made by the Company which are not historical facts may be considered forward-looking statements, including, and without limitation, statements as to trends, management's beliefs, expectations and opinions, which are based upon a number of assumptions concerning future conditions that ultimately may prove to be inaccurate. Such forward-looking statements are subject to risks and uncertainties and may be affected by various factors, which may cause actual results to differ materially from those forward-looking statements.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:May 7, 2003
Previous Article:VSoft Corporation Announces Availability of SPICE; Technology Improves Check Processing Efficiencies in One Pass.
Next Article:Avenue A Presents ``Digital Nirvana -- a Year in Review'' at Annual Client Summit.

Related Articles
A heartening finding for women on aspirin.
Cardiac surgery in patients with moderate renal impairment.
Section on Cardiology. (Abstracts of Scientific Posters).
Unappreciable myocardial bridge causing anterior myocardial infarction and postinfarction angina. (Case Report).
Clinical predictors of 30-day cardiac events in patients with acute coronary syndrome at a community hospital.
Electroconvulsive therapy-associated acute coronary syndrome in the absence of coronary artery disease.
Smallpox vaccination and adverse cardiac events.
CAR-11. Syndrome X: a bit of a mystery.
How to improve the management of chest pain: hospitalists and use of prediction rules.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters